Quick Takeaways
- Woodline Partners LP filed SCHEDULE 13G for SAB Biotherapeutics, Inc. Common Stock, par value $0.0001 per share (SABS).
- Disclosed ownership: 9.9%.
- Date of event: 30 Sep 2025.
Woodline Partners LP - 30 Sep 2025 SCHEDULE 13G Report for SAB Biotherapeutics, Inc. Common Stock, par value $0.0001 per share (SABS)
- Filing Manager
- Woodline Partners LP
- Reporting Manager
- Woodline Partners LP
- Symbol
- SABS
- Shares outstanding
- 71,978,596 shares
- Disclosed Ownership
- 7,125,881 shares
- Ownership
- 9.9%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Nov 2025, 16:18:27 UTC
- Date of event
- 30 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Woodline Partners LP disclosed 9.9% ownership in SAB Biotherapeutics, Inc. Common Stock, par value $0.0001 per share (SABS) on 30 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Nov 2025, 16:18.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Woodline Partners LP | 9.9% | 7,125,881 | 7,125,881 | 0 | /s/ Erin Mullen | Erin Mullen, General Counsel & Chief Compliance Officer |